A practical reference on Nicotinamide mononucleotide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-05 and is reviewed periodically as new material appears.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Nucleotide derivative of nicotinamide |
| Molecular formula | C11H15N2O8P | Free acid form; salts may differ |
| Molar mass | 334.22 g/mol | Approximate value for free acid |
| CAS Registry Number | 1094-61-7 | Common beta isomer |
| Solubility | Water-soluble | Polar molecule; solubility varies with pH and form |
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
== Paint and printing thickeners == One of the main use of thickeners is in the paint and printing industries, which depend heavily on rheology modifiers, to prevent pigments settling to the bottom of the can, yielding inconsistent results. Water based formulas would be nearly impossible with the exception of India ink and the few other water-soluble pigments, but these would have very little coverage and at best would stain wood slightly. All modern paints and inks will have some pigment added at the factory for opacity and to control the specularity of the finish, from matte to high gloss, dependent on thickener used, but more so on the size of the particles added as opacity modifier. Particle sizes of 1 μm and below will be the limit of high gloss, probably confined to luxury automotive coatings, and about 100 μm particulates will make a bumpy surface on the microscopic scale, which scatters light and makes the surface appear matte. Rheology modifiers in common use:
=== Threshold intake levels for adverse effects === Adverse health and social effects associated with kava consumption—such as skin rashes, increased body mass index (BMI), elevated gamma-glutamyl transferase (GGT) enzyme levels, and higher lymphocyte counts—may begin to appear at intake levels of approximately 240 to 440 grams of kava powder per week, corresponding to 3,500 to 6,440 mg of kavalactones per day. One shell of kava contains an average of 250 mg kavalactones. Published and anecdotal evidence further indicates that recreational consumption of kava beverages can often exceed these levels, surpassing the kavalactone doses used in clinical settings for the treatment of anxiety, which are aqueous extracts containing 140–250 mg, taken once per day over six weeks, have demonstrated no significant toxicity.
A police investigation into claims former Conservative MP Mark Menzies misused donors' money to pay "bad people" is dropped after he agreed to repay the money. Former Conservative minister Maria Caulfield, who lost her seat at the last election, joins Reform UK. Mark McEwan steps down as Standards Commissioner at Stormont a week after his appointment to take up the post of Deputy Chief Constable of Surrey Police. 17 September – Mason Humberstone, a member of Stevenage Borough Council, becomes the first Labour Party councillor to defect to Reform UK. 18 September – The Newham Independents win a local by-election in Plaistow South. 19 September – The Terminally Ill Adults (End of Life) Bill passes its second reading in the House of Lords. Jamie Hepburn resigns as the Scottish Government's Minister for Cabinet and Parliamentary Business following a complaint that he assaulted former Conservative leader Douglas Ross as the two were leaving the Scottish Parliament building two days earlier. Wales's Health Minister, Jeremy Miles, announces he will not stand in the 2026 Senedd election. John Allen, a councillor on Northumberland County Council, is suspended from Reform UK following allegations he made online threats to kill the prime minister. A schism breaks out between Zarah Sultana and Jeremy Corbyn over Your Party. Andy Burnham says he "isn't ruling out" a return to Westminster politics. 20 September – The Liberal Democrat conference starts in Bournemouth. Gavin Robinson launches the Democratic Unionist Party conference in Belfast.
Sources: en.wikipedia.org
However, the topical application of 1–3% solutions of the drug to the nasal mucosa of patients with sinusitis did produce a beneficial constriction without local irritation. Administration of synephrine by continuous intravenous infusion, at the rate of 4 mg/minute, significantly increased mean arterial and systolic pressure, but diastolic pressure and heart rate were unaltered.; further details of this investigation are summarized in a review by Fugh-Berman and Myers. There are a number of studies, references to many of which may be found in the review by Stohs and co-workers dealing with the effects produced by dietary supplements and herbal medications that contain synephrine as only one of many different chemical ingredients. These are outside the scope of the present article (see also the "Safety/Efficacy/Controversy" sub-section).
=== Neurotransmitter === Aspartate (the conjugate base of aspartic acid) stimulates NMDA receptors, though not as strongly as the amino acid neurotransmitter L-glutamate does. Aspartate is the "A" in NMDA (N-methyl-D-aspartate receptor).
. They are calculated for the Gaussian distribution of asperities, which have been shown to be unrealistic for engineering surface but can be assumed where friction, load carrying capacity or real contact area results are not critical to the analysis.
Sources: en.wikipedia.org
NMN is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis. It consists of nicotinamide attached to a ribose phosphate unit. Cells produce it through the salvage pathway.
NMN is converted to NAD+ by NMNAT enzymes. NAD+ is a coenzyme in redox reactions and a substrate for signaling enzymes. This relationship makes NMN a focus of NAD+ research.
No, NMN and nicotinamide riboside are distinct compounds. Nicotinamide riboside can be phosphorylated to form NMN inside cells. Both are studied as NAD+ precursors.
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide intermediate in NAD+ biosynthesis.